Literature DB >> 21593166

Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner.

Toshana L Foster1, Philippe Gallay, Nicola J Stonehouse, Mark Harris.   

Abstract

NS5A plays a critical, yet poorly defined, role in hepatitis C virus genome replication. The protein consists of three domains, each of which is able to bind independently to the 3' untranslated region (UTR) of the viral positive strand genomic RNA. The peptidyl-prolyl isomerase cyclophilin A (CypA) binds to domain II, catalyzing cis-trans isomerization. CypA inhibitors such as cyclosporine (CsA) have been shown to inhibit hepatitis C virus (HCV) replication. We show here that CypA stimulated domain II RNA binding activity, and this stimulation was abrogated by CsA. An isomerase mutant of CypA (H126Q) failed to bind to domain II and did not stimulate RNA binding. Finally, we demonstrate that the RNA binding of two domain II mutants, the D316E and D316E/Y317N mutants, previously shown to exhibit CypA independence for RNA replication, was unaffected by CypA. This study provides an insight into the molecular mechanism of CypA activity during HCV replication and further validates the use of CypA inhibitors in HCV therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593166      PMCID: PMC3126559          DOI: 10.1128/JVI.00393-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

Review 1.  Cyclophilin inhibitors for the treatment of HCV infection.

Authors:  Gunter Fischer; Philippe Gallay; Sam Hopkins
Journal:  Curr Opin Investig Drugs       Date:  2010-08

2.  Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.

Authors:  Sandra Ciesek; Eike Steinmann; Heiner Wedemeyer; Michael P Manns; Johann Neyts; Norbert Tautz; Vanesa Madan; Ralf Bartenschlager; Thomas von Hahn; Thomas Pietschmann
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

3.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

4.  The NS5A protein of hepatitis C virus is a zinc metalloprotein.

Authors:  Timothy L Tellinghuisen; Joseph Marcotrigiano; Alexander E Gorbalenya; Charles M Rice
Journal:  J Biol Chem       Date:  2004-08-31       Impact factor: 5.157

5.  All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding.

Authors:  Toshana L Foster; Tamara Belyaeva; Nicola J Stonehouse; Arwen R Pearson; Mark Harris
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

6.  Molecular and structural characterization of the domain 2 of hepatitis C virus non-structural protein 5A.

Authors:  Yu Liang; Cong Bao Kang; Ho Sup Yoon
Journal:  Mol Cells       Date:  2006-08-31       Impact factor: 5.034

7.  Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein.

Authors:  Luyun Huang; Jungwook Hwang; Suresh D Sharma; Michele R S Hargittai; Yingfeng Chen; Jamie J Arnold; Kevin D Raney; Craig E Cameron
Journal:  J Biol Chem       Date:  2005-08-25       Impact factor: 5.157

8.  The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.

Authors:  Udayan Chatterji; Michael Bobardt; Suganya Selvarajah; Feng Yang; Hengli Tang; Noayo Sakamoto; Gregoire Vuagniaux; Tanya Parkinson; Philippe Gallay
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

9.  Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins.

Authors:  Jungwook Hwang; Luyun Huang; Daniel G Cordek; Robert Vaughan; Shelley L Reynolds; George Kihara; Kevin D Raney; C Cheng Kao; Craig E Cameron
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

10.  Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded.

Authors:  Yu Liang; Hong Ye; Cong Bao Kang; Ho Sup Yoon
Journal:  Biochemistry       Date:  2007-09-19       Impact factor: 3.162

View more
  57 in total

Review 1.  Anti-HCV drugs in the pipeline.

Authors:  Priscilla L Yang; Min Gao; Kai Lin; Qingsong Liu; Valerie A Villareal
Journal:  Curr Opin Virol       Date:  2011-11-13       Impact factor: 7.090

Review 2.  Entangled in a membranous web: ER and lipid droplet reorganization during hepatitis C virus infection.

Authors:  Nathan L Meyers; Krystal A Fontaine; G Renuka Kumar; Melanie Ott
Journal:  Curr Opin Cell Biol       Date:  2016-05-27       Impact factor: 8.382

3.  Hepatitis C virus replication compartment formation: mechanism and drug target.

Authors:  Vineela Chukkapalli; Glenn Randall
Journal:  Gastroenterology       Date:  2014-03-25       Impact factor: 22.682

4.  Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative.

Authors:  Wataru Ito; Masaaki Toyama; Mika Okamoto; Masanori Ikeda; Koichi Watashi; Takaji Wakita; Yuichi Hashimoto; Masanori Baba
Journal:  Antivir Chem Chemother       Date:  2016-08-19

Review 5.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

6.  Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.

Authors:  Hawwa Alao; Maggie Cam; Chithra Keembiyehetty; Fang Zhang; Elisavet Serti; Daniel Suarez; Heiyoung Park; Nicolaas H Fourie; Elizabeth C Wright; Wendy A Henderson; Qisheng Li; T Jake Liang; Barbara Rehermann; Marc G Ghany
Journal:  Hepatology       Date:  2018-07-16       Impact factor: 17.425

Review 7.  Treating hepatitis C infection by targeting the host.

Authors:  Shadi Salloum; Andrew W Tai
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

8.  Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry.

Authors:  Malgorzata Bienkowska-Haba; Carlyn Williams; Seong Man Kim; Robert L Garcea; Martin Sapp
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

9.  Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.

Authors:  Adriaan H de Wilde; Yanhua Li; Yvonne van der Meer; Grégoire Vuagniaux; Robert Lysek; Ying Fang; Eric J Snijder; Martijn J van Hemert
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 10.  Hepatitis C virus-host interactions, replication, and viral assembly.

Authors:  Ana Shulla; Glenn Randall
Journal:  Curr Opin Virol       Date:  2012-10-18       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.